|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
9
|
|
pubmed:dateCreated |
2009-11-17
|
|
pubmed:abstractText |
Hyperuricemia and posttransplantation erythrocytosis (PTE) are frequent complications after kidney transplantation and are important risk factors for cardiovascular events. Losartan decreases serum uric acid and hemoglobin (Hb) concentrations and may be a useful agent for treatment of hyperuricemia and PTE.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Nov
|
|
pubmed:issn |
1873-2623
|
|
pubmed:author |
|
|
pubmed:issnType |
Electronic
|
|
pubmed:volume |
41
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
3736-42
|
|
pubmed:meshHeading |
pubmed-meshheading:19917377-Adult,
pubmed-meshheading:19917377-Angiotensin II,
pubmed-meshheading:19917377-Blood Pressure,
pubmed-meshheading:19917377-Case-Control Studies,
pubmed-meshheading:19917377-Cyclosporine,
pubmed-meshheading:19917377-Female,
pubmed-meshheading:19917377-Humans,
pubmed-meshheading:19917377-Hyperuricemia,
pubmed-meshheading:19917377-Immunosuppressive Agents,
pubmed-meshheading:19917377-Kidney Transplantation,
pubmed-meshheading:19917377-Losartan,
pubmed-meshheading:19917377-Male,
pubmed-meshheading:19917377-Middle Aged,
pubmed-meshheading:19917377-Polycythemia,
pubmed-meshheading:19917377-Prospective Studies,
pubmed-meshheading:19917377-Receptor, Angiotensin, Type 1,
pubmed-meshheading:19917377-Safety,
pubmed-meshheading:19917377-Uric Acid
|
|
pubmed:year |
2009
|
|
pubmed:articleTitle |
Efficacy and safety of losartan in treatment of hyperuricemia and posttransplantation erythrocytosis: results of a prospective, open, randomized, case-control study.
|
|
pubmed:affiliation |
Center for Renal Transplantation, Jiulisong Hospital, Zhejiang, China.
|
|
pubmed:publicationType |
Journal Article,
Randomized Controlled Trial
|
